N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 2 N=10 STAR Cape+BKM120 MBC With Brain Met
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Phase 2 N=37 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms, Male · Carcinoma, Ductal
Primary: Overall Tumor Response — 1; 8; 14; 9 participants
Phase 2 N=140 MEtronomic TrEatment Option in Advanced bReast cAncer
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Phase 2 N=83 Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 3 N=475 A Phase III Trial For Patients With Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
N/A N=129 Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy
Disseminated HER2+ Breast Cancer
Primary: The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) — 63.5; 48.8; 84.1; 41.1 percentage of participants
Phase 2 N=160 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
Phase 2 N=18 Herceptin and GM-CSF for Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=23 Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Phase 2 N=70 Combination Chemotherapy for Metastatic Breast Cancer
Breast Cancer
Primary: Objective Tumor Response — 7; 19; 19; 5 participants
Phase 2 N=63 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 3 N=564 S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
Breast Cancer
Primary: Overall Survival — 10.7; 12.5 months — p=0.98
Phase 2 N=48 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=38 Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Metastatic Breast Cancer · Breast Cancer · Progressive Breast Cancer
Primary: Central Nervous System (CNS) Objective Response Rate — 63 percentage of participants
Phase 2 N=147 Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
Breast Cancer
Primary: Best Overall Response — 1; 0; 1; 12 participants
Phase 4 N=44 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Phase 2 N=55 Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
Breast Cancer · Metastatic Cancer
Primary: Central Nervous System (CNS) Progression-free Survival(PFS) — 12; 2 participants
Early Phase 1 N=20 Cabergoline in Metastatic Breast Cancer
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
N/A N=236 Telephone Support for Metastatic Breast Cancer Patients
Metastatic Breast Cancer
Primary: Fatigue Interference Subscale of Fatigue Symptom Inventory — 2.96; 3.66; 3.24; 3.43 units on a scale — p=.018
Phase 2 N=111 A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Phase 2 N=10 Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 4.8 months